Loading…
ALFUZOSIN HCL is a brand name for Alfuzosin. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Treatment of the functional symptoms of benign prostatic hyperplasia (BPH).
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults The usual dose is one tablet three times daily. The dose may be increased to a maximum of 4 tablets (10 mg) per day depending on the clinical response. Elderly and treated hypertensive patients As a routine precaution when prescribing alfuzosin to elderly patients (aged over 65 years) and the treated hypertensive patient, the initial dose should be 1 tablet in the morning and 1 tablet in the evening.
5mg twice daily adjusted according to clinical response. 5 mg Tablets twice daily according to clinical response. 3). 1). Therefore, alfuzosin is not indicated for use in paediatric population. 5 mg film-coated tablets should be swallowed whole.
The first dose should be given just before bedtime.
Tabulated list of adverse reactions The adverse reactions considered at least possibly related to treatment are listed below by body system organ class and absolute frequency. Frequencies are defined as very common (≥1/10); common (>1/100 to <1/10); uncommon (>1/10000 to ≤1/1000); very rare (≤1/10000), not known (cannot be estimated from the available data).
System Organ Class Frequency Common Uncommon Very rare Not Known (Cannot be estimated from the available data) Blood and lymphatic system disorders Neutropenia thrombocytopenia Nervous system disorders Faintness/ dizziness, headache, vertigo Syncope, drowsiness Eye disorders vision abnormal Intraoperative floppy iris syndrome Cardiac disorders tachycardia, palpitations, Angina pectoris in patients with pre-existing coronary artery disease Atrial fibrillation Vascular disorders Hypotension (postural) Flushing Respiratory, thoracic and medicinal disorders rhinitis Gastrointestinal disorders nausea, abdominal pain, diarrhoea, dry mouth vomiting Hepatobiliary disoders hepatotoxicity Hepatocellular injury, cholestatic liver disease Reproductive system and breast disorders Priapism Skin and subcutaneous tissue disorders rashe pruritus, urticaria, angioedema General disorders and administration site conditions Asthenia, malaise Oedema, chest pain Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Blood pressure should be monitored at the start of treatment. A reduction in blood pressure may arise in individual cases. Alfuzosin HCl should be given with caution to patients who are on antihypertensive medication or nitrates. In some subjects postural hypotension may develop, with or without symptom (dizziness, fatigue, sweating) within a few hours following administration.
These effects are transient, occur in the beginning of treatment and do not usually prevent the continuation of treatment. Pronounced drop in blood pressure has been reported in post-marketing surveillance in patients with pre-existing risk factors (such as underlying cardiac diseases and/or concomitant treatment with anti-hypertensive medication).
8). The patient should be warned of the possible occurrence of such events. In cases of orthostatic hypotension the patient should lie or sit down until the symptoms have disappeared. Care should be taken when alfuzosin is administered to patients who have had a pronounced hypotensive response to another alpha-1-blocker.
In coronary patients, the specific treatment for coronary insufficiency should be continued. If angina pectoris reappears or worsens, alfuzosin should be discontinued. As with all alpha-1-blockers, alfuzosin should be used with caution in patients with acute cardiac failure.
- lung oedema due to mitral or tricuspidal stenosis, - high output cardiac failure, - cardiac failure due to pulmonary embolism or pericardial effusion Patients with congenital QTc prolongation, with a known history of acquired QTc prolongation or who are taking drugs known to increase the QTc interval should be evaluated before and during the administration of alfuzosin The patient should be examined prior to treatment with alfuzosin to exclude other conditions, which may cause the same symptoms as benign prostatic hyperplasia.
A digital rectal examination should be performed prior to treatment and regularly during treatment. A prostate specific antigen (PSA) test should also be carried out if required. 5). g. itraconazole and clarithromycin) and a temporary interruption of alfuzosin treatment is recommended if treatment with such medicinal products is initiated.
Hypersensitivity to the active substance alfuzosin, another quinazolines (eg: terazosine, doxazosine) or to any of the excipients. - History of orthostatic hypotension. - Combination with other alfa1-blockers and / or dopamine receptor agonists.
- Severe hepatic insufficiency
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Alfuzosin in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
The ‘Intraoperative Floppy Iris Syndrome’ (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with tamsulosin. Isolated reports have also been received with other alpha-1 blockers and the possibility of a class effect cannot be excluded.
As IFIS may lead to increased procedural complications during the cataract operation current or past use of alpha-1 blockers should be made known to the ophthalmic surgeon in advance of surgery. 8). Because this condition can lead to permanent impotence if not properly treated, patients should be advised to seek immediate assistance in the event of an erection that persists longer than 4 hours.
Alfuzosin should not be used in patients suffering from incontinence due to overflow, anuria or prolonged renal insufficiency. Alfuzosin HCl contains lactose Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Patients should be warned that the tablet should be swallowed whole. Any other mode of administration, such as crunching, crushing, chewing, grinding or pounding to powder should be prohibited. These actions may lead to inappropriate release and absorption of the drug and therefore possible early adverse reactions.
’